Medicine and HealthNature Communications
Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants
T. Li, W. Xue, et al.
This groundbreaking study uncovers two powerful cross-neutralizing antibodies, 7D6 and 6D6, targeting the conserved Sarbecovirus receptor-binding domain, providing promising avenues for therapeutic and vaccine development against diverse SARS-CoV-2 variants. Conducted by a team of expert researchers, including Tingting Li and Wenhui Xue, this work is a leap forward in the fight against COVID-19.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes
D. Sun, Z. Sang, et al.
Medicine and Health
A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
L. M. Coria, J. M. Rodriguez, et al.
Medicine and Health
A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
X. Zhang, H. Zhang, et al.
Medicine and Health
Human antibodies to SARS-CoV-2 with a recurring YYDRXG motif retain binding and neutralization to variants of concern including Omicron
H. Liu, C. I. Kaku, et al.
